Fusion Pharmaceuticals Inc, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.


"We are pleased to welcome Dmitri to Fusion's leadership team at a time when Fusion has three Phase 1 novel targeted alpha therapy (TAT) programs and a multi-product development collaboration with AstraZeneca," said Fusion Chief Executive Officer John Valliant, Ph.D. "Dmitri brings to our team his expertise as a seasoned drug developer and practicing medical and radiation oncologist with an impressive track record of success and clinical trial planning and execution. We look forward to his leadership in guiding our clinical development programs as we seek to bring our TATs to cancer patients in need."


Dr. Bobilev joins Fusion from Checkmate Pharma, where he was vice president, head of clinical development until the company's acquisition by Regeneron earlier in 2022. At Checkmate, he was responsible for clinical development strategy for vidutolimod. Prior to Checkmate, Dr. Bobilev was vice president, head of clinical development at Vedanta Biosciences. He previously held clinical development leadership roles with Tesaro and Sanofi. Dr. Bobilev spent more than 10 years as a practicing medical and radiation oncologist.


Dr. Bobilev commented, "The next wave of radiopharmaceuticals based on alpha emitting isotopes are poised to make a significant impact on the landscape of cancer therapy. Fusion has established itself as a leader in targeted alpha therapies, combining internal R&D capabilities, with manufacturing and supply chain expertise to create a fully-integrated radiopharmaceutical company. I'm excited about the opportunity to guide the clinical strategy for a company with such a rich pipeline of innovative cancer therapies."


Source: Fusion Pharmaceuticals

«« World Diabetes Day: Increase Diabetes Prevention and Care


Urgent Policy Action Needed to Promote Physical Activity »»



Latest Articles

Fusion Pharmaceuticals, clinical-stage oncology company,radiopharmaceuticals,precision medicines, Dmitri Bobilev, chief medical officer Fusion Pharmaceuticals Inc, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines announced...